Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of AL-335 + odalasvir + simeprevir in non-cirrhotic chronic hepatitis C
2015-004200-38Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of adafosbuvir, odalasvir and simeprevir in chronic hepatitis C (CHC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Sustained virologic response at 12 weeks after end of treatment. Started May 2016; status: completed.
02
Drugs
adafosbuvirodalasvirsimeprevir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2015-004200-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004200-38.